

I hereby certify that this correspondence is being delivered by hand to:

Technology Center 1600  
Assistant Commissioner for Patents  
Washington, D.C. 20231

On 12/09/02

TOWNSEND and TOWNSEND and CREW LLP

By: MAHAN VO

**PATENT**  
Attorney Docket No.: 015270-006430US  
Client Reference No.: 228-US-NEW

RECEIVED  
TECH CENTER 1600/2900  
02 DEC -9 PM 1:15

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

John P. Anderson et al.

Application No.: 09/471,669

Filed: December 24, 1999

For: BETA-SECRETASE ENZYME  
COMPOSITIONS AND METHODS

Examiner: Malgorzata A. Walicka

Art Unit: 1652

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

**RECEIVED**

DEC 10 2002

TECH CENTER 1600/2900

Technology Center 1600  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Cite no. 78 is a copy of the International Search Report issued for the corresponding International application, PCT/US00/03819. Cite No. 65 is a copy of a press release announcing that Elan Corporation, plc and Pharmacia Corporation entered into a research collaboration focused on the discovery of small molecule inhibitors of beta-secretase for the

treatment of Alzheimer's disease. Elan Pharmaceuticals, Inc. assignee of the instant application, is affiliated with Elan Corporation, plc.

Applicants also cite commonly owned copending applications and issued patents directed to related subject matter:

08/480,498, filed 06/07/95, issuing as US Patent 5,744,346 on April 28, 1998;  
08/485,152, filed 06/07/95;  
08/659,984, filed 06/07/96, issuing as US Patent 5,942,400 on August 24, 1999;  
08/660,531, filed 06/07/96, issuing as US Patent 6,221,645 on April 24, 2001;  
09/054,334, filed 04/02/98, issuing as US Patent 6,329,163 on December 11, 2001;  
09/404,578, filed 09/23/99;  
09/471,669, filed 12/24/99;  
09/501,708, filed 02/10/00;  
09/723,722, filed 11/28/00;  
09/723,739, filed 11/28/00;  
09/724,568, filed 11/28/00;  
09/724,566, filed 11/28/00;  
09/724,569, filed 11/28/00;  
09/724,571, filed 11/28/00; and,  
10/099,922, filed 03/15/02;

Applicants further cites the following commonly owned abandoned applications directed to related subject matter:

60/114,408, filed 12/31/98;  
60/119,571, filed 02/10/99;  
60/139,172, filed 06/15/99;  
60/168,854, filed 12/02/99; and,  
09/730,329, filed 12/04/00.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference

should be made that the information and references cited are prior art merely because they are in this statement.

This Information Disclosure Statement has been filed prior to receipt of the first Office Action on the merits, and consequently should be considered by the Patent Office without payment of a fee according to 37 CFR §1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli  
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 650-326-2400  
Fax: 650-326-2422  
RLC:rlc  
PA 3269250 v1